 |
 |
|
|
|
| CAD031 Powder |
 |
| C18H14F6N2O2 |
 |
| 2071209-49-7 |
 |
CAD031,also known as CAD-31.CAD-31 is a derivative of the experimental drug J147.It is a novel compound that has been developed as a potential therapeutic option for Alzheimer’s disease (AD).CAD-31 exhibits enhanced neurogenic activity over J147 in human neural precursor cells,meaning it has a stronger ability to stimulate the replication of these cells.Additionally,CAD-31 has been found to promote the utilization of free fatty acids for energy production by shifting the metabolic profile of fatty acids towards the production of ketone bodies.Ketone bodies serve as an alternative source of energy in the brain when glucose levels are low.
The target molecule of CAD-31 is ATP synthase,a protein found in the mitochondria.By targeting ATP synthase,CAD-31 aims to modulate mitochondrial function and energy metabolism in the brain.This modulation of energy metabolism may have potential implications for neurodegenerative diseases such as Alzheimer’s disease.
It’s important to note that CAD-31 is still under investigation and further research is needed to fully understand its efficacy,safety profile,and potential as a therapeutic intervention for AD.The supply of CAD031 powder is not big in the market.Only few of company can synthesize this material.CAD031 supplier AASRAW can supply high purity CAD031 powder.With our independant lab and professional R&D team,the CAD031 wholesale supply is not a problem.
Benefits:
CAD031,as an Alzheimer’s disease (AD) drug candidate,has shown several potential benefits based on available research:
1.Neuroprotective Properties: CAD031 has been found to possess potent neuroprotective properties in multiple nerve cell assays that mimic toxicities observed in the aging brain.This suggests that CAD031 has the potential to protect neurons from damage and degeneration.
2.Reduction of Memory Deficits: In a mouse model of AD,CAD031 has demonstrated therapeutic efficacy by reducing memory deficits.When administered to old,symptomatic AD mice,CAD031 led to a decrease in memory impairment,indicating its potential for improving cognitive function.
3.Decreased Brain Inflammation: CAD031 has been observed to reduce brain inflammation in AD mice.By reducing inflammatory responses in the brain,CAD031 may help mitigate the detrimental effects associated with neurodegenerative diseases.
4.Increased Synaptic Protein Expression: CAD031 treatment has been shown to increase the expression of synaptic proteins in the brain.Synaptic proteins are essential for maintaining healthy connections between neurons and play a crucial role in cognitive function.The increase in synaptic protein expression suggests a potential for CAD031 to support synaptic health.
5.Effects on Fatty Acid Metabolism and Inflammation: CAD031 has been found to have a major impact on fatty acid metabolism and inflammation pathways.This suggests that CAD031 may modulate these processes,potentially leading to a favorable impact on brain health and neurodegenerative conditions. |
 |
medical use
|
 |
Molecular Weight:404.312
Melting Point: N/A
Color: White solid powder
|
|
|
|
 |
 |
|
AASraw/Aea.ltd
|
| 전화번호 |
+13204026693 |
| 팩스번호 |
|
| 홈페이지 |
- |
| 이메일 |
King@aea.ltd
|
| 주소 |
FLAT/RM C1 4/F SUMMIT BUILDING 30 MAN YUE STREET HUNG HOM,HONG KONG,CHINA |
|
 |
|
|
|
|
|
|
|
|
